Radiation Biological Toximetry Using Circulating Cell-Free DNA (cfDNA) for Rapid Radiation/Nuclear Triage

被引:1
|
作者
Okunieff, Paul [1 ]
Swarts, Steven G. [1 ]
Fenton, Bruce [3 ]
Zhang, Steven B. [1 ]
Zhang, Zhenhuan [1 ]
Rice, Lori [1 ]
Zhou, Daohong [4 ]
Carrier, France [5 ]
Zhang, Lurong [1 ,2 ]
机构
[1] Univ Florida, Dept Radiat Oncol, Gainesville, FL USA
[2] Fujian Med Univ, Affiliated Hosp 1, Fuzhou 350005, Peoples R China
[3] Univ Rochester, Sch Med & Dent, Med Ctr, Rochester, NY USA
[4] Univ Texas Hlth San Antonio, Dept Biochem & Struct Biol, Ctr Innovat Drug Discovery CIDD, San Antonio, TX USA
[5] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
EARLY DOSE ASSESSMENT;
D O I
10.1667/RADE-23-00159.1
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Optimal triage biodosimetry would include risk stratification within minutes, and it would provide useful triage despite heterogeneous dosimetry, cytokine therapy, mixed radiation quality, race, and age. For regulatory approval, the U.S. Food and Drug Administration (FDA) Biodosimetry Guidance requires suitability for purpose and a validated species-independent mechanism. Circulating cell-free DNA (cfDNA) concentration assays may provide such triage information. To test this hypothesis, cfDNA concentrations were measured in unprocessed monkey plasma using a branched DNA (bDNA) technique with a laboratory developed test. The cfDNA levels, along with hematopoietic parameters, were measured over a 7-day period in Rhesus macaques receiving total body radiation doses ranging from 1 to 6.5 Gy. Low-dose irradiation (0-2 Gy) was easily distinguished from high-dose whole-body exposures (5.5 and 6.5 Gy). Fold changes in cfDNA in the monkey model were comparable to those measured in a bone marrow transplant patient receiving a supralethal radiation dose, suggesting that the lethal threshold of cfDNA concentrations may be similar across species. Average cfDNA levels were 50 +/- 40 ng/mL [+/- 1 standard deviation (SD)] pre-irradiation, 120 +/- 13 ng/mL at 1 Gy; 242 +/- 71 ng/mL at 2 Gy; 607 +/- 54 at 5.5 Gy; and 1585 +/- 351 at 6.5 Gy (+/- 1 SD). There was an exponential increase in cfDNA concentration with radiation dose. Comparison of the monkey model with the mouse model and the Guskova model, developed using Chernobyl responder data, further demonstrated correlation across species, supporting a similar mechanism of action. The test is available commercially in a Clinical Laboratory Improvement Amendments (CLIA) ready form in the U.S. and the European Union. The remaining challenges include developing methods for further simplification of specimen processing and assay evaluation, as well as more accurate calibration of the triage category with cfDNA concentration cutoffs. (C) 2024 by Radiation Research Society
引用
收藏
页码:70 / 79
页数:10
相关论文
共 50 条
  • [31] Circulating cell-free methylated DNA reveals tissue-specific, cellular damage from radiation treatment
    McNamara, Megan E.
    Loyfer, Netanel
    Kiliti, Amber J.
    Schmidt, Marcel O.
    Shabi-Porat, Sapir
    Jain, Sidharth S.
    Roth, Sarah Martinez
    McDeed, A. Patrick
    Shahrour, Nesreen
    Ballew, Elizabeth
    Lin, Yun-Tien
    Li, Heng-Hong
    Mays, Anne Deslattes
    Rudra, Sonali
    Riegel, Anna T.
    Unger, Keith
    Kaplan, Tommy
    Wellstein, Anton
    JCI INSIGHT, 2023, 8 (14)
  • [32] CIRCULATING CELL-FREE NUCLEAR DNA IS ASSOCIATED WITH FIBRINOLYTIC SHUTDOWN AFTER INJURY
    Kutcher, Matthew E.
    Carter, Kristen T.
    Rieske, Richard R.
    Pastukh, Viktor M.
    Gillespie, Mark N.
    Simmons, Jon D.
    SHOCK, 2019, 51 (06): : 37 - 38
  • [33] Elevated levels of circulating cell-free DNA in interventional cardiologists occupationally exposed to low levels of ionizing radiation
    Borghini, A.
    Mercuri, A.
    Turchi, S.
    Piccaluga, E.
    Guagliumi, G.
    Picano, E.
    Andreassi, M. G.
    EUROPEAN HEART JOURNAL, 2014, 35 : 206 - 206
  • [34] DETECTION OF POINT MUTATIONS AND GENE FUSIONS FROM CIRCULATING CELL-FREE DNA (CFDNA) OF GLIOBLASTOMA (GBM) PATIENTS
    Frenkel-Morgenstern, Milana
    Palande, Vikrant
    Detroja, Rajesh
    Gorohovski, Alessandro
    Glass, Rainer
    Flueh, Charlotte
    Kanner, Andrew A.
    Laviv, Yoseph
    Nof, Sagi Har
    Levy-Barda, Adva
    Benouaich-Amiel, Alexandra
    Yust-Katz, Shlomit
    Kurtz, Marina
    Perez, Shira
    Shay, Dorith Raviv
    Siegal, Tali
    NEURO-ONCOLOGY, 2020, 22 : 169 - 169
  • [35] Development of a comprehensive cell-free DNA (cfDNA) assay for early detection of multiple tumor types: The Circulating Cell-free Genome Atlas (CCGA) study.
    Klein, Eric A.
    Hubbell, Earl
    Maddala, Tara
    Aravanis, Alex
    Beausang, John F.
    Filippova, Darya
    Gross, Samuel
    Jamshidi, Arash
    Kurtzman, Kathryn
    Shen, Ling
    Valouev, Anton
    Venn, Oliver
    Zhang, Nan
    Smith, David A.
    Yeatman, Timothy Joseph
    Tibshirani, Robert
    Williams, Richard Thomas
    Hartman, Anne-Renee
    Seiden, Michael
    Liu, Minetta C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Development of plasma cell-free DNA (cfDNA) assays for early cancer detection: first insights from the Circulating Cell-Free Genome Atlas Study (CCGA)
    Aravanis, Alexander A.
    Oxnard, Geoffrey R.
    Maddala, Tara
    Hubbell, Earl
    Venn, Oliver
    Jamshidi, Arash
    Shen, Ling
    Amini, Hamed
    Beausang, John A.
    Betts, Craig
    Civello, Daniel
    Davydov, Konstantin
    Fazullina, Saniya
    Filippova, Darya
    Gnerre, Sante
    Gross, Samuel
    Hou, Chenlu
    Jiang, Roger
    Jung, Byoungsok
    Kurtzman, Kathryn
    Melton, Collin
    Nautiyal, Shivani
    Newman, Jonathan
    Newman, Joshua
    Nicolaou, Cosmos
    Rava, Richard
    Sakarya, Onur
    Satya, Ravi Vijaya
    Shojaee, Seyedmehdi
    Steffen, Kristan
    Valouev, Anton
    Xu, Hui
    Yue, Jeanne
    Zhang, Nan
    Baselga, Jose
    Lapham, Rosanna
    Davis, Daron G.
    Smith, David
    Richards, Donald
    Seiden, Michael V.
    Swanton, Charles
    Yeatman, Timothy J.
    Tibshirani, Robert
    Curtis, Christina
    Plevritis, Sylvia K.
    Williams, Richard
    Klein, Eric
    Hartman, Anne-Renee
    Liu, Minetta C.
    CANCER RESEARCH, 2018, 78 (13)
  • [37] Role of Circulating Cell-Free DNA in Cancers
    Raghu Aarthy
    Samson Mani
    Sridevi Velusami
    Shirley Sundarsingh
    Thangarajan Rajkumar
    Molecular Diagnosis & Therapy, 2015, 19 : 339 - 350
  • [38] Circulating cell-free DNA in hematological malignancies
    Buedts, Lieselot
    Vandenberghe, Peter
    HAEMATOLOGICA, 2016, 101 (09) : 997 - 999
  • [39] Cell-free circulating tumor DNA in cancer
    Zhen Qin
    Vladimir ALjubimov
    Cuiqi Zhou
    Yunguang Tong
    Jimin Liang
    ChineseJournalofCancer, 2016, 35 (05) : 205 - 213
  • [40] Life and death of circulating cell-free DNA
    Kustanovich, Anatoli
    Schwartz, Ruth
    Peretz, Tamar
    Grinshpun, Albert
    CANCER BIOLOGY & THERAPY, 2019, 20 (08) : 1057 - 1067